ELV
Income statement / Annual
Last year (2024), Elevance Health Inc.'s total revenue was $176.81 B,
an increase of 3.19% from the previous year.
In 2024, Elevance Health Inc.'s net income was $5.98 B.
See Elevance Health Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$176.81 B |
$171.34 B |
$156.60 B |
$138.64 B |
$121.87 B |
$104.21 B |
$92.11 B |
$90.04 B |
$84.86 B |
$79.16 B |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$176.81 B
|
$171.34 B
|
$156.60 B
|
$138.64 B
|
$121.87 B
|
$104.21 B
|
$92.11 B
|
$90.04 B
|
$84.86 B
|
$79.16 B
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.25 B
|
$11.17 B
|
$11.09 B
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.40 B
|
$1.39 B
|
$1.44 B
|
| Selling, General & Administrative Expenses |
$0.00
|
$0.00
|
$17.69 B
|
$15.91 B
|
$17.45 B
|
$13.36 B
|
$14.02 B
|
$12.65 B
|
$12.56 B
|
$12.53 B
|
| Other Expenses |
$168.91 B
|
$163.63 B
|
$131.31 B
|
$114.73 B
|
$98.18 B
|
$84.86 B
|
$73.02 B
|
$73.43 B
|
$67.75 B
|
$61.99 B
|
| Operating Expenses |
$168.91 B
|
$163.63 B
|
$149.00 B
|
$130.64 B
|
$115.63 B
|
$98.23 B
|
$87.04 B
|
$86.08 B
|
$80.31 B
|
$74.53 B
|
| Cost And Expenses |
$168.91 B
|
$163.63 B
|
$149.00 B
|
$130.64 B
|
$115.63 B
|
$98.23 B
|
$87.04 B
|
$86.08 B
|
$80.31 B
|
$74.53 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$1.19 B
|
$1.03 B
|
$851.00 M
|
$798.00 M
|
$784.00 M
|
$746.00 M
|
$753.00 M
|
$739.00 M
|
$723.00 M
|
$653.00 M
|
| Depreciation & Amortization |
$1.39 B
|
$1.75 B
|
$1.68 B
|
$1.30 B
|
$1.15 B
|
$1.13 B
|
$1.13 B
|
$891.00 M
|
$912.00 M
|
$907.90 M
|
| EBITDA |
$10.48 B |
$10.49 B |
$10.13 B |
$10.10 B |
$8.18 B |
$7.86 B |
$6.95 B |
$5.59 B |
$6.19 B |
$6.19 B |
| EBITDA Ratio |
0.06
|
0.06
|
0.06
|
0.07
|
0.07
|
0.08
|
0.08
|
0.06
|
0.07
|
0.08
|
| Operating Income Ratio |
0.04
|
0.05
|
0.05
|
0.06
|
0.05
|
0.06
|
0.06
|
0.04
|
0.05
|
0.06
|
| Total Other Income/Expenses Net |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Income Before Tax |
$7.90 B
|
$7.72 B
|
$7.60 B
|
$8.00 B
|
$6.24 B
|
$5.99 B
|
$5.07 B
|
$3.96 B
|
$4.56 B
|
$4.63 B
|
| Income Before Tax Ratio |
0.04
|
0.05
|
0.05
|
0.06
|
0.05
|
0.06
|
0.06
|
0.04
|
0.05
|
0.06
|
| Income Tax Expense |
$1.93 B
|
$1.72 B
|
$1.71 B
|
$1.85 B
|
$1.67 B
|
$1.18 B
|
$1.32 B
|
$121.00 M
|
$2.09 B
|
$2.07 B
|
| Net Income |
$5.98 B
|
$5.99 B
|
$5.89 B
|
$6.16 B
|
$4.57 B
|
$4.81 B
|
$3.75 B
|
$3.84 B
|
$2.47 B
|
$2.56 B
|
| Net Income Ratio |
0.03
|
0.03
|
0.04
|
0.04
|
0.04
|
0.05
|
0.04
|
0.04
|
0.03
|
0.03
|
| EPS |
25.81 |
25.38 |
24.56 |
25.25 |
18.23 |
18.81 |
14.53 |
14.7 |
9.39 |
9.73 |
| EPS Diluted |
25.68 |
25.22 |
24.28 |
24.73 |
17.98 |
18.47 |
14.19 |
14.35 |
9.21 |
9.38 |
| Weighted Average Shares Out |
$232.87 M
|
$233.07 M
|
$240.00 M
|
$243.80 M
|
$250.80 M
|
$255.50 M
|
$254.30 M
|
$256.08 M
|
$263.75 M
|
$261.24 M
|
| Weighted Average Shares Out Diluted |
$232.90 M
|
$237.40 M
|
$242.80 M
|
$246.80 M
|
$254.30 M
|
$260.30 M
|
$254.30 M
|
$267.80 M
|
$268.10 M
|
$272.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
